Diabetes Market Forecast to 2013 (TA221)

Product Profiles

Type I Antidiabetic Treatments

* Traditional Insulins
o Novolin
o Humulin
* Short-Acting Insulin Analogs
o Novolog
o Humalog
o Apidra
* Long-Acting Insulin Analogs
o Levemir
o Lantus
* Other Drugs
o Symlin
o Technosphere
o Teplizumab
o Otelixuzumab
o TT-223

Type II Antidiabetic Treatments

* DPP-4 Inhibitors
o Januvia (includes Janumet)
o Galvus (includes Eucreas)
o Alogliptin
o Onglyza
* GLP-1 Analogs
o Byetta (includes Byetta Long-Acting Release)
o Liraglutide
o AVE0010
o Syncria
o Tapsoglutide
* SGLT-2 Inhibitors
o AVE2268
o Remogliflozin
o Dapagliflozin
* Sulfonylureas
o Amaryl
o Glucotrol
* Thiazolidinediones (TZDs)
o Avandia (includes Avandamet and Avandaryl)
o Actos (includes Actoplus Met and Duetact)
* Meglitinides
o Prandin
o Starlix
o Glufast
* Alpha-Glucosidase Inhibitors
o Precose
o Glyset
* Other
o Acomplia
o MBX-102
o AGI-1067
o XOMA052
o SRT501
o MB07803
o ISIS113715

Adjunct Therapies

* Cymbalta
* Arxxant
* Avapro
* Cozaar
* Lyrica
* Zyvox
* Regranex
* Lucentis
* Atacand
* Epicept NP-1
* Qnexa

PRODUCT PROFILE COMPONENTS

* Drug’s development and approval history
* Competitive and strategic positioning
o Current status of drug, including approval history
o Current and projected competitive strengths/vulnerabilities
o Current and projected sales position within class
* Market growth opportunities
o Analysis combines current sales, market landscape and/or clinical trial info with projections and predicted market events
o Sales projection charts for next 4-7 years
o Materiality charts (drug's percentage of company revenue) for 2007 and 2012
* Patents and generics charts containing market exclusivity and patent information for approved drugs
* Clinical trial data tables
o Summary of most important trials
o Trial title and objective
o Start and end dates